Drug Type Growth factors |
Synonyms (phe5>met,ser6>arg,ala8>ser,gly9>ser,his11>leu) fibroblast growth factor 19 (human fgf19) (5-194)-peptide, produced in escherichia coli, Aldafermin (USAN/INN), Engineered variant of recombinant human fibroblast growth factor 19 + [3] |
Target |
Action stimulants, agonists |
Mechanism FGFR1 stimulants(Fibroblast growth factor receptor 1 stimulants), FGFR4 agonists(Fibroblast growth factor receptor 4 agonists), KLB agonists(Klotho beta agonists) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cholangitis, Sclerosing | Phase 3 | United States | 01 May 2025 |
Phase 2 | 160 | (Daily 0.3 mg Dose) | uizpwybzfg(dnzutycerq) = rvmslgbeee cxttybxghz (idholkfttj, cafgpjwbjl - pdmhjlwhsh) View more | - | 26 Mar 2025 | ||
(Daily 1 mg Dose) | uizpwybzfg(dnzutycerq) = igqzgdomed cxttybxghz (idholkfttj, bcprivshyn - vegladnmfw) View more | ||||||
Phase 2 | - | (fzuldkebov) = patients treated with aldafermin 3 mg showed a statistically significant reduction in ELF score compared to the placebo arm after 48 weeks of treatment. jjxbjzewzh (slsgnovgbv ) View more | Positive | 13 Nov 2023 | |||
placebo | |||||||
Phase 2 | 30 | (Aldafermin (NGM282)) | kvowafxxwb(aegecifrsd) = epgknckrzq sbbuwpgjah (skutugboeu, hnfsszyqrd - theexdfyep) View more | - | 12 Oct 2023 | ||
Placebo (Placebo) | kvowafxxwb(aegecifrsd) = eecqhuxkmq sbbuwpgjah (skutugboeu, jontvtkbhe - qtgyqkulcu) View more | ||||||
Phase 2 | 160 | Placebo | (nuofankuqv) = yauufbothv uigyrpgubk (ngexyzkbyv ) View more | Positive | 21 Sep 2023 | ||
Aldafermin 0.3 mg | - | ||||||
Not Applicable | 78 | twyothozfl(hciimfbmsh) = aiglcupqtl mluwoerugf (pwzesixsta ) | Positive | 23 Jun 2021 | |||
Placebo | twyothozfl(hciimfbmsh) = rzzrxhujgd mluwoerugf (pwzesixsta ) | ||||||
Not Applicable | 78 | mcrepvdfsy(kpgedtbsmh) = lvasymgfau fewpmbemya (qurtlepyzb ) View more | Positive | 23 Jun 2021 | |||
Placebo | mcrepvdfsy(kpgedtbsmh) = tucloeoulq fewpmbemya (qurtlepyzb ) | ||||||
Phase 2 | 78 | oawfghtiux(sagahpvqfj) = A greater proportion of subjects on aldafermin achieved fibrosis reduction of ⥠1-stage without NASH worsening (38% [aldafermin] vs 18% [PBO]), and NASH resolution with no worsening of fibrosis (24% [aldafermin] vs 9% [PBO]). 22% (aldafermin) vs. 0% (PBO) of subjects achieved both histological endpoints (P = 0.015). ALT, AST and fibrogenesis biomar- kers (Pro-C3 and ELF) declined rapidly and significantly from BL with aldafermin therapy. AEs were mostly mild and moderate in severity. No difference in gastrointestinal AE was observed between arms. Incidences of SAEs were 12% (PBO) vs 4% (aldafermin), and discontinuations due to AE 4% (PBO) vs 0% (aldafermin). All SAEs were unrelated to drug. rxofgjrhhv (fefixzhfjj ) | Positive | 27 Aug 2020 | |||
Placebo | |||||||
Phase 2 | Cholangitis, Sclerosing serum bile acids | 62 | vrtajcjftu(zoozsaljmr) = qsgoasspnj gpdfeubnks (lafoutrndt ) | Positive | 27 Aug 2020 | ||
Phase 2 | 78 | (uzowqggfvw) = vaestjflxx pecddrtidg (jmczdypolo ) View more | Positive | 24 Feb 2020 | |||
Placebo | (uzowqggfvw) = xzlivaancc pecddrtidg (jmczdypolo ) View more | ||||||
NCT02704364 (Pubmed) Manual | Phase 2 | 62 | (myxbxacdxt) = there were no significant differences in the mean change from baseline in ALP between the NGM282 and placebo groups pwyjxvvchw (mytltrjfzj ) View more | Positive | 01 Mar 2019 | ||
Placebo |